Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026
Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026
Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026
Same author

The Unfinished Story: Analyzing Publication Rates in Diabetic Retinopathy and Diabetic Macular Edema Trials Before the COVID-19 Era (1972-2018).

Rhode Island medical journal (2013)·2025
Same author

CD8+ Regulatory T Cells.

Annual review of immunology·2025
Same author

Oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid.

Taiwan journal of ophthalmology·2025

Related Experiment Video

Updated: Jun 9, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: a prospective, randomized pilot

Karina Quinones1, John Y Choi, Taygan Yilmaz

  • 1Massachusetts Eye Research and Surgery Institution, Cambridge, MA, USA.

Ocular Immunology and Inflammation
|August 26, 2010
PubMed
Summary

Pars plana vitrectomy (PPV) demonstrated higher efficacy in resolving intermediate uveitis (IU) compared to immunomodulatory therapy (IMT). PPV led to significant improvements in visual acuity and inflammation reduction, warranting further investigation.

Related Experiment Videos

Last Updated: Jun 9, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Intermediate uveitis (IU) is a chronic inflammatory condition affecting vision.
  • Recalcitrant IU often requires advanced treatment strategies to manage inflammation and preserve visual acuity.

Purpose of the Study:

  • To compare the efficacy of pars plana vitrectomy (PPV) versus immunomodulatory therapy (IMT) for treating intermediate uveitis.
  • To evaluate the impact of PPV and IMT on visual acuity, intraocular pressure, and ocular inflammation.

Main Methods:

  • A prospective, randomized pilot study involving patients with recalcitrant IU.
  • Patients were randomized to receive either PPV or IMT.
  • Key outcome measures included visual acuity, intraocular pressure, and anterior chamber/vitreous cellularity.

Main Results:

  • Pars plana vitrectomy (PPV) achieved a significantly higher rate of inflammation resolution (82%) compared to IMT (57%) in intermediate uveitis.
  • PPV also demonstrated greater improvements in visual acuity, intraocular pressure, and reduction of vitreous cells.
  • Cystoid macular edema (CME) resolved in all PPV-treated eyes, with improvement in 2 of 3 IMT-treated eyes.

Conclusions:

  • Pars plana vitrectomy (PPV) appears more effective than immunomodulatory therapy (IMT) for managing intermediate uveitis.
  • Further multicentered clinical trials are necessary to statistically validate these findings and confirm PPV's superiority.